https://padiracinnovation.org/News/2021/04/better-drainage-of-brain-debris-improves-alzheimers-disease-therapies Rubriques * Logo Padirac Innovation * Posts about research * Permanent Posts * Interesting Pubmed articles * Jobs * How to contribute * RSS feed * [ ] Home Home >> English >> Better drainage of brain debris improves Alzheimer's disease therapies Better drainage of brain debris improves Alzheimer's disease therapies 28 April 2021 - Posted in English by admin In most of the organs of our body, the lymphatic system is responsible for conducting lymph between different parts of the body. The lymphatic system processes an average of 3 liters of lymph per day. Lymph lies between the blood vessels and the cells. The lymphatic system provides a return route to the blood vessels for lymph. Lymph also allows immune cells to circulate in the lymph nodes, allowing immune surveillance of body tissues. It was historically believed that the brain and meninges lacked a lymphatic vascular system. For more than a century, the dominant hypothesis was that the flow of cerebrospinal fluid, could replace peripheral lymphatic functions and play an important role in the clearance of extracellular fluids. It was recently discovered (2014) by Jonathan Kipnis and other scientists that a pathway connects the glymphatic system (a recently discovered central nervous system waste disposal system) to the meningeal compartment, which surrounds the brain and the spinal cord. enter image description here Pathologically, neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and Huntington's disease are all characterized by progressive loss of neurons, cognitive decline, motor impairments, and sensory loss. Collectively, these diseases fall into a broad category called proteopathies due to the common assembly of misfolded or aggregated intracellular or extracellular proteins. According to the dominant hypothesis of Alzheimer's disease, the aggregation of amyloid-beta in extracellular plaques leads to neuronal loss and cerebral atrophy which is the hallmark of Alzheimer's dementia. For 2O years anti-amyloid clinical trials failed. Recently an anti-amyloid drug, Biogen and Eisai's aducanumab, has shown mixed efficacy in clinical trials in slowing cognitive decline. A research team led by pioneers such as Jonathan Kipnis, offers a possible explanation for these disappointing clinical results. Jonathan Kipnis describes the meningeal lymphatic system as a waste disposal system for the central nervous system. If aducanumab or other drugs targeting misfolded proteins break these aggregates, but the debris cannot be removed due to deficiencies in the meningeal lymphatic system, then the patient's condition cannot improve. Therefore improving the function of lymphatic drainage may have a positive impact on the effectiveness of this type of medication. To test this theory, Kipnis and his colleagues used versions of aducanumab and another drug targeting amyloids, BAN2401, in a mouse model of Alzheimer's disease. Mice with impaired lymphatic drainage systems showed a higher accumulation of beta-amyloid plaque than controls with intact drainage systems. They also displayed a decreased influx of antibody drugs into the brain from the surrounding fluid. Changes in a type of immune cell in the brain called microglia, which shed dying cells and other debris, was also observed. When the lymphatic drainage was blocked it caused the microglia to go into an inflammatory state. To explore the therapeutic potential of drugs acting on the meningeal lymphatic system, scientists combined aducanumab or BAN2401 with a C-virus-mediated vascular endothelial growth factor, in hopes of expanding the network of meningeal lymphatics. Mice treated with this therapy showed significantly reduced beta-amyloid accumulation compared to those who received only anti-amyloid drugs. These findings suggest that it may be possible to develop drugs that target microglia and blood vessels in the brain - both of which are important in Alzheimer's disease - by modulating lymphatic vessel function. Advertisement [51pNZDKvmIL] This book retraces the main achievements of ALS research over the last 30 years, presents the drugs under clinical trial, as well as ongoing research on future treatments likely to be able stop the disease in a few years and to provide a complete cure in a decade or two. Alzheimer --------------------------------------------------------------------- Related Posts Oligomerix montre qu'un... Les proteines Tau stabilisent les microtubules assurant la... more Studies of tears in the case... Alzheimer's disease is a severe neurodegenerative disease... more Biogen n'a pas obtenu le... Le traitement experimental de la maladie d'Alzheimer de... more --------------------------------------------------------------------- Previous Post * Recent Posts * Popular Posts Recent Posts Better drainage of brain debris improves Alzheimer's... In most of the organs of our body, the lymphatic system is responsible for... Read more Improving cardiovascular fitness in midlife to escape... Cardiovascular fitness reflects an organism's ability to supply oxygen to... Read more Increased Accumulation of a-Synuclein in Inflamed... Alpha-synuclein is a neuronal protein that regulates synaptic vesicle... Read more Everything points to mTOR dysfunction in ALS Here we review recent publications about ALS and try to connect the dots... Read more Can infrared light improve symptoms of Parkinson's... An international clinical trial, is investigating whether infrared light... Read more Muscle cells of sporadic ALS patients secrete neurotoxic... Amyotrophic lateral sclerosis is a non-cell autonomous disease, and motor... Read more Enhanced insulin signalling ameliorates C9orf72... The insulin signaling pathway plays a crucial role in regulating the... Read more An ALS therapy poses a moral dilemma to Biogen It was found in 2009 that toxicity of SOD1 is secondary to a gain of toxic... Read more Popular Posts Enhanced insulin signalling ameliorates C9orf72... The insulin signaling pathway plays a crucial role in regulating the... Read more Nasal administration of mitochondria reverses... Nearly 3 out of 4 cancer patients undergoing chemotherapy suffer from loss... Read more Donanemab is the first anti-amyloid drug to meet a clinical... It has been clear for a while that anti-amyloid antibodies can sweep... Read more Alteration in sarcoplasmic reticulum activity underlies... A new article by Qaisar, Qayum and Muhammad made me think about links... Read more An ALS therapy poses a moral dilemma to Biogen It was found in 2009 that toxicity of SOD1 is secondary to a gain of toxic... Read more Kaempferol alleviates mitochondrial damage in a mice model... Parkinson's disease is a common neurodegenerative disease. Although the... Read more Development of an a-synuclein knockdown peptide and... Parkinson's disease (Parkinson's disease) is a major neurodegenerative... Read more Can infrared light improve symptoms of Parkinson's... An international clinical trial, is investigating whether infrared light... Read more Everything points to mTOR dysfunction in ALS Here we review recent publications about ALS and try to connect the dots... Read more Improving cardiovascular fitness in midlife to escape... Cardiovascular fitness reflects an organism's ability to supply oxygen to... Read more Archive * V 2021 (31) + April (8) + March (7) + February (9) + January (7) * > 2020 (110) + December (9) + November (8) + October (7) + September (6) + August (9) + July (6) + June (10) + May (8) + April (9) + March (8) + February (15) + January (15) * > 2019 (208) + December (16) + November (16) + October (16) + September (8) + August (16) + July (4) + June (10) + May (111) + April (10) + February (1) Search [ ] Languages * English * Francais * Uncategorized * Zhong Wen Please, to help us continue to provide valuable information: Donate with PayPal button * Tags Alzheimer Dementia (Demence) Sla Cancer Als Parkinson Neurodegenerative disease Multiple sclerosis (sclerose en plaque) clinical trial (essais clinique) gene therapy (therapies geniques) Drug resistance (resistance medicamenteuse) Heart failure (insuffisance cardiaque) Neglected drugs (medicaments delaisses) FAQ cancer acellular-systems Aging Als alteration genetique Alzheimer analgesie annonces anthelminthique anxiete ASO Asthma AVXS 101 benin biologie-synthetique biomarqueur boston-university bronchoscopy business c9orf72 Cachexie cancer cancer-de-la-vessie cancer-du-poumon cancer-du-rein cancer-metastatique cancerigene cancerogenese capteurs car-t-cell carcinogenese cart-t CD34 CEA changements-emotionnels changements-physiques cognition colere Couvertures lestees Culpabilisation culpabilite cytokine depistage depression diagnostic douleur Duchenne ECM ecologie-cellulaire Entrectinib epigenetique essais cliniques etat precancereux Facteurs environnementaux faq-cancer fenbendazole fibrose-de-pontage FTD ganglion gene therapy gilead google grossesse groupe-de-soutien guanabenz Heart hippocampe IL 2 Imaging immunotherapie incertitude inclusions inflammation insuffisance cardiaque introduction johnson-johnson-innovation kymriah LATE lesion lesion precancereuse listes lusc lymphome malin marqueur melanocytes met-amplification MIROCALS mucoviscidose myelofibrose nash Neurodegenerative disease Neuromodulation Neuroregeneration Neuroscience neutrophil nom notre histoire nscl nsclc obesite osimertinib Parkinson patient pd-1 pd-l1 pd-l2 Perampanel peurs pexidartinib Pimozide prevention propagation protocole racotumomab Ranolazine Rapamycin resistance revolution risque savolitinib sclerose en plaques selonsertib selumetinib Senescence senescent sensors SLA SMA soins palliatifs Speculation steatose-hepatique-non-alcoolique stellar stress surveillance symptome system-biology systemes-acellulaires tabac TDP 43 therapie-genique tissus topique transdifferentiation TUDCA vermifuge yescarta Zolgensma Yan Zheng Contactez nous a "contact at padiracinnovation dot org" Notre histoire